Investors have found chocolate stocks to be an appealing investment since they have experienced financial gains. As of ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Last week was another busy week for the White House, with several notable Executive Orders and more agency leadership changes ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

The widely followed cryptocurrency analyst Benjamin Cowen is warning that Ethereum (ETH) could slide further against Bitcoin ...

While Michigan's constitution forbids the use of public money for private school, President Trump could sidestep a ...

Cowen challenged students to rethink the intersection of society and artificial intelligence at a Yale Political Union debate ...

TD Cowen maintained a positive stance on Planet Fitness (NYSE:PLNT) shares, reiterating a Buy rating and a price target of ...

TD Cowen initiated coverage of Repligen (RGEN) with a Buy rating and $200 price target Repligen is well positioned for “industry-leading” ...

China-based GDS Holdings (GDS) is surging 6% after investment bank TD Cowen raised its price target on the shares. The ...

In a report released today, Marc Bianchi from TD Cowen maintained a Buy rating on NOV (NOV – Research Report), with a price target of $22.00.

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...